Current approaches for the management of patients with high-risk multiple myeloma

There are currently multiple strategies to treat patients with high-risk multiple myeloma. In this video, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, outlines how patients with high-risk disease are treated at Emory University. Patients first receive carfilzomib-lenalidomide-dexamethasone (KRd) induction therapy before undergoing autologous stem cell transplantation (autoSCT) followed by KRd consolidation and maintenance for three years. This strategy is based on the results of the FORTE study (NCT02203643) which showed that this patient population benefited from this regimen and achieved sustained measurable residual disease (MRD) negativity. There are currently discussions about incorporating daratumumab in this regimen, but clinical trials have not yet shown a significant benefit for this high-risk population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.